Pain outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving enzalutamide (ENZA) in a real-world setting: PREMISEDavid Mott, Marco Pavesi, Angus Robinson et al.|European Urology Open Science|2020Cited by 0